Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Benitec prices initial public offering of 1,500,000 American Depositary Shares

Benitec Biopharma Limited, a clinical-stage biotechnology company, is pleased to announce the pricing of its U.S. initial public offering of 1,500,000 American Depositary Shares (ADSs), representing 30,000,000 fully paid ordinary shares of Benitec and warrants to purchase 500,000 ADSs, representing 10,000,000 fully paid ordinary shares, at a price of US$9.21 per ADS and US$0.01 per warrant.

18 Aug 2015

Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Omeros Corporation today announced additional positive data in the company's Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies (TMAs). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) – aggregations of platelets – in the microcirculation of the body's organs, most commonly the kidney and brain.

18 Aug 2015

CMU BrainHub scientists use non-invasive brain-imaging tool to detect basal ganglia pathways

Certain diseases, like Parkinson's and Huntingdon's disease, are associated with damage to the pathways between the brain's basal ganglia regions. The basal ganglia sits at the base of the brain and is responsible for, among other things, coordinating movement. It is made up of four interconnected, deep brain structures that imaging techniques have previously been unable to visualize.

18 Aug 2015

Omeros plans to file patent infringement lawsuit against Par

Omeros Corporation today, in response to investor questions, announced that it plans to file a patent infringement lawsuit against Par Pharmaceutical, Inc. and its subsidiary, Par Sterile Products, LLC in response to the Abbreviated New Drug Application (ANDA) filed by Par seeking FDA approval to market a generic version of Omeros' commercial drug Omidria (phenylephrine and ketorolac injection) 1%/0.3%.

17 Aug 2015

Determining the dynein-dynactin complex structure: an interview with Dr Gabriel C. Lander

This is a macromolecular assembly is made up of two components, dynein and dynactin, that works to move molecular cargo (organelles, RNA, vesicles, proteins, viruses) along microtubule highways within our cells.

16 Aug 2015

FDA accepts sNDA to review Brintellix clinical trial data for treatment of major depressive disorder

Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) announced today the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for review to add clinical data regarding the effect of Brintellix (vortioxetine) on certain aspects of cognitive function in adults with Major Depressive Disorder (MDD) to the current product label.

11 Aug 2015

Researchers report role of two gene-regulating molecules in Parkinson's disease

As Parkinson's disease progresses in patients, a puzzling dichotomy plays out in their brains. One set of neurons degenerates, while a similar population nearby is spared the same degree of damage. Why the difference? An answer to this question could clear the way for preventions and treatments for this disease, which impairs movement.

11 Aug 2015

Discovery may lead to new ways to diagnose, treat brain cancer

Researchers at the Virginia Bioinformatics Institute have uncovered a link between the genomes of cells originating in the neural crest and development of tumors — a discovery that could lead to new ways to diagnose and treat cancer.

6 Aug 2015

Omeros receives EC approval to market Omidria in EU and other European countries

Omeros Corporation today announced that the European Commission (EC) has granted marketing authorization for Omidria (phenylephrine and ketorolac injection) 1% / 0.3% in the European Union (EU) for use in cataract surgery and lens replacement procedures to maintain mydriasis (pupil dilation), prevent miosis (pupil constriction), and to reduce postoperative eye pain.

3 Aug 2015

Redox equilibrium may help identify new diagnostic biomarkers for ageing, neurodegenerative processes

The question of why we age is one of the most fascinating questions for humankind, but nothing close to a satisfactory answer has been found to date.

3 Aug 2015

DNA study reveals potential treatments to delay or prevent onset of Huntington's disease

Scientists from Cardiff University believe that a treatment to prevent or delay the symptoms of Huntington’s disease could now be much closer, following a major breakthrough.

31 Jul 2015

Study sheds light on certain antagonist drugs that block physiological responses

Members of the Consolidated Research Group of Molecular Neurobiology of the Department of Biochemistry and Molecular Biology of the University of Barcelona (UB), affiliated with the Centre for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), have published a study in the journal Proceedings of the National Academy of Sciences (PNAS) about the formation of G protein-coupled receptors (GPCRs) which allows understanding the unexpected behaviour of some antagonists that block physiological responses.

30 Jul 2015

Lupin signs strategic asset purchase agreement with Temmler

Pharma Major Lupin Limited today announced that it has entered into a strategic asset purchase agreement with TEMMLER PHARMA GMBH & CO. KG, a part of the Aenova Group, one of the world's largest pharmaceutical contract manufacturers, to acquire Temmler's specialty product portfolio subject to certain closing conditions.

25 Jul 2015

Omeros' OMS721 granted FDA Fast Track designation for treatment of atypical hemolytic uremic syndrome

Omeros Corporation today announced that the U.S. Food and Drug Administration granted Fast Track designation to OMS721 for the treatment of patients with atypical hemolytic uremic syndrome (aHUS). OMS721 is the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system.

23 Jul 2015

Researchers use gene-editing technique involving low-dose irradiation to repair human stem cells

For the first time, researchers have employed a gene-editing technique involving low-dose irradiation to repair patient cells, according to a study published in the journal Stem Cells Translational Medicine. This method, developed by researchers in the Cedars-Sinai Board of Governors Regenerative Medicine Institute, is 10 times more effective than techniques currently in use.

23 Jul 2015

Imperial College London researchers discover new inherited form of obesity, type 2 diabetes

Scientists have discovered a new inherited form of obesity and type 2 diabetes in humans. A large number of genes are involved in regulating body weight, and there are now over 30 genes known in which people with harmful changes in DNA sequence become extremely overweight. Similarly, there are a number of genes that can, when altered, cause type 2 diabetes. These conditions are inherited through families in exactly the same way as disorders such as cystic fibrosis or Huntington's disease.

30 Jun 2015

New Internet tool may help analyze genes based on their evolutionary profile

Two major revolutions, one genomic and one in informatics, are completely changing the face of biomedical research. Every day all over the world, millions of genetic sequences -- from disease-related genes to complete genomes of plants, animals, bacteria and viruses -- are resolved, identified and dissected.

26 Jun 2015

Discovery may accelerate development of new drugs to treat Huntington's disease

By identifying in spinal fluid how the characteristic mutant proteins of Huntington's disease spread from cell to cell, UC Irvine scientists and colleagues have created a new method to quickly and accurately track the presence and proliferation of these neuron-damaging compounds -- a discovery that may accelerate the development of new drugs to treat this incurable disease.

24 Jun 2015

Benitec, ReNeuron collaborate to launch new exploratory cellular therapy program

Benitec Biopharma is pleased to announce the launch of a new exploratory cellular therapy program including exosome-based delivery utilising the Company's proprietary ddRNAi technology. Entry into these areas have been facilitated by the commencement of a collaboration with UK-based stem cell therapeutics company, ReNeuron.

22 Jun 2015

TSRI study confirms role of Rhes protein in Huntington's disease

Huntington's disease attacks the part of the brain that controls movement, destroying nerves with a barrage of toxicity, yet leaves other parts relatively unscathed.

17 Jun 2015

Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Benitec prices initial public offering of 1,500,000 American Depositary Shares

Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

CMU BrainHub scientists use non-invasive brain-imaging tool to detect basal ganglia pathways

Omeros plans to file patent infringement lawsuit against Par

Determining the dynein-dynactin complex structure: an interview with Dr Gabriel C. Lander

FDA accepts sNDA to review Brintellix clinical trial data for treatment of major depressive disorder

Researchers report role of two gene-regulating molecules in Parkinson's disease

Discovery may lead to new ways to diagnose, treat brain cancer

Omeros receives EC approval to market Omidria in EU and other European countries

Redox equilibrium may help identify new diagnostic biomarkers for ageing, neurodegenerative processes

DNA study reveals potential treatments to delay or prevent onset of Huntington's disease

Study sheds light on certain antagonist drugs that block physiological responses

Lupin signs strategic asset purchase agreement with Temmler

Omeros' OMS721 granted FDA Fast Track designation for treatment of atypical hemolytic uremic syndrome

Researchers use gene-editing technique involving low-dose irradiation to repair human stem cells

Imperial College London researchers discover new inherited form of obesity, type 2 diabetes

New Internet tool may help analyze genes based on their evolutionary profile

Discovery may accelerate development of new drugs to treat Huntington's disease

Benitec, ReNeuron collaborate to launch new exploratory cellular therapy program

TSRI study confirms role of Rhes protein in Huntington's disease

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in